← FDA DRUG APPROVALS

FDA ANDA · ANDA206552

HEPARIN SODIUM

Sponsor: FRESENIUS KABI USA

APPLICATION
ANDA206552
TYPE
ANDA
ORIGINAL APPROVAL
2016-06-10
LATEST ACTION
2020-11-02
ROUTE
INTRAVENOUS, SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

HEPARIN SODIUMPrescription
HEPARIN SODIUM 5,000 UNITS/ML · INJECTABLE · INJECTION

Approval history

2020-11-02Labeling · Supplement 1 · standardAP
2016-06-10UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →